Medicine and Dentistry
Receptor Subtype
100%
Histone Deacetylase Inhibitor
100%
Somatostatin Receptor
100%
Receptor Modulation
100%
Carcinoid
100%
Surface Receptor
100%
Neoplasm
22%
Positron Emission Tomography
22%
Romidepsin
22%
Somatostatin Derivative
22%
Carcinoid Cell Line
22%
Upregulation
11%
In Vitro
11%
Xenograft
11%
Targeted Therapy
11%
Lung Cancer
11%
Vorinostat
11%
Neuroendocrine Tumor
11%
Sodium Valproate
11%
Fluorodeoxyglucose F 18
11%
Keyphrases
Cell Surface Receptor
100%
Histone Deacetylase Inhibitor (HDACi)
100%
Somatostatin Receptor 2 (SSTR2)
100%
Pulmonary Carcinoid
100%
Receptor Modulation
100%
Tumor
22%
Positron Emission tomography-CT
22%
Radiolabeled Somatostatin Analogs
22%
Non-cytotoxic
22%
Overexpressing
11%
Thailandepsin A
11%
Lung Cancer
11%
CT-based
11%
FK228
11%
Romidepsin
11%
Xenograft
11%
Metabolic Activity
11%
Targeted Treatment
11%
Cancer Cases
11%
Specific Treatment
11%
18F-fluorodeoxyglucose (18F-FDG)
11%
Valproic Acid
11%
Neuroendocrine Tumor
11%
Suberoylanilide Hydroxamic Acid
11%
Sugar Analog
11%
Pharmacology, Toxicology and Pharmaceutical Science
Receptor
100%
Histone Deacetylase Inhibitor
100%
Receptor Subtype
100%
Somatostatin Receptor
100%
Carcinoid
100%
Neoplasm
22%
Romidepsin
22%
Somatostatin Derivative
22%
Lung Cancer
11%
Sodium Valproate
11%
Vorinostat
11%
Fluorodeoxyglucose F 18
11%
Neuroendocrine Tumor
11%